China Biologic Completes $360 Million Follow-On Offering

On June 15, 2015, China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, completed its follow-on public offering with an aggregate offer size of more than $360 million, consisting of 3,450,000 shares of common stock sold by the company and certain of its existing stockholders at a price to the public of $105 per share.

WSGR represented the company and the selling stockholders in connection with the offering. Morgan Stanley & Co. International plc, Credit Suisse Securities (USA) LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, and Jefferies LLC acted as joint book-running managers for the offering and Lazard Frères & Co. LLC acted as a co-manager.

The WSGR team was led by partners Weiheng Chen, Steven Bernard, and Dan Ouyang, and included Jie Zhu, Ava Zhao, and Ke Li.